Exabis Library
Welcome to the e-CCO Library!
P694: COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P694: Disease course during the first five years following diagnosis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P694: Genetic predisposition and thiopurine-induced pancreatitis in inflammatory bowel disease patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P694: Long-term monitoring of post-surgical recurrence in Crohn's disease using a strategy based on the periodic determination of fecal calprotectin in patients without early postoperative recurrence
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P694: Non-medical mandatory reversed and back and forth switch between infliximab and its biosimilar: Early clinical outcomes
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P695 Vedolizumab induction and maintenance though levels and long-term clinical and biochemical status in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P695: Attitudes and predictors of COVID-19 vaccine uptake in patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P695: Does anticoagulation treatment increase the rate of major bleeding complications in patients with IBD and venous thromboembolism?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P695: Effectiveness and Safety of Combination Biologic or Small Molecule Therapy in Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P695: Feasibility and safety of strictureplasties performed by laparoscopic approach for complicated Crohn’s disease: A prospective observational cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P695: The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P696 The usefulness to treatment enhancement for the patients of ulcerative colitis with clinical remission diagnosed as Mayo endoscopic subscore 1
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P696: Ambient air quality as risk factor for microscopic colitis – a Geographic Information System study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P696: Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P696: Faecal microbiota transplantation in ultra-refractory ulcerative colitis: Retrospective analysis in a tertiary care centre
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P696: Genetic predisposition to infliximab immunogenicity in patients with immune-mediated inflammatory diseases – secondary analyses from a randomised clinical trial
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P696: Long-term prognosis and predictive factors for surgical treatment of intestinal lesions in patients with Behcet’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P697 Efficacy and safety of ustekinumab in Crohn’s disease: A real-world study from Australia
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P697: Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulator(s)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P697: Association of inflammatory bowel disease and celiac disease. Experience in a hospital of the autonomous community of Madrid (Spain)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM